Huddinge

• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404 … Halted
  2023-505096-68-00 4 2025-01-14 Preclinical Alzheimer’s Disease
• A study to investigate whether treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients. Halted
  2023-508397-29-00 4 2022-06-29 Prophylaxis against liver allograft rejection following tolerance indu
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 4 2025-11-25 Alzheimer's Disease
• A Phase 1/2 Study of VX-522 in Subjects with Cystic Fibrosis Ended
  2023-504786-23-00 7 2024-11-18 Cystic Fibrosis
• A Study to assess the safety and potential use of GEH121224 (18F) Injection to visualise HER2-Receptor expression using PET imaging in patie … Ended
  2023-507720-23-00 9 2024-11-15 Metastatic breast cancer
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2024-511998-30-00 5 2024-10-18 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos … Ended
  2023-506000-50-00 4 2024-09-26 Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
• A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease Ended
  2023-506805-20-01 5 2024-09-25 Neurodegenerative Diseases
• A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1) Ended
  2023-508556-18-00 1 2024-09-25 Crimean Congo Hemorrhagic Fever
• PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease. Ended
  2024-512992-11-00 3 2024-08-30 Crohn's disease
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• Transfer of prednisolone into human breast milk and plasma of breastfeeding children Ended
  2023-508913-18-00 6 2024-03-05 Reumatoid Arthritis, SLE, myositis, psoriatric arthritis, inflammatory
• A24110He in a placebo-controlled trial evaluating safety in subjects with elevated plasma triglycerides Ended
  2023-509091-42-00 4 2024-02-27 Moderate to severe hypertriglyceridemia
• A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe … Ended
  2022-501884-41-00 5 2023-09-29 Contrast enhancement in magnetic resonance imaging for assessment of c
• PET study of changes in [11C]AZ14132516 uptake following administration of AZD7798 to healthy participants and patients with Crohn’s disease Ended
  2023-505471-78-00 3 2023-09-25 Crohn's Disease
• A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno … Ended
  2022-501885-24-00 5 2023-09-20 Contrast enhancement in magnetic resonance imaging for assessment of n
• A trial to evaluate safety and characteristics of a substance for treatment of chronic hepatitis Ended
  2023-503880-40-00 4 2023-09-19 Chronic hepatitis B
• A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and … Ended
  2022-502382-25-00 4 2023-08-24 Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WH
• APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with … Ended
  2023-503244-14-00 7 2023-08-11 Relapsed or Refractory Acute Myeloid Leukemia (AML)
• A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer's disease Ended
  2023-506825-13-00 5 2023-07-25 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient … Ended
  2023-506837-31-00 4 2023-01-27 New onset type I diabetes
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation

Showing 169–192 of 215 trials